Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Aldape

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Acta Neuropathologica|December 3, 2016
Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor TaxonomyDavid N Louis, Ken Aldape, Daniel J Brat, et al.
Neuro-Oncology|December 15, 2010
Risk factors for oligodendroglial tumors: a pooled international studyBridget J McCarthy, Kristin M Rankin, Ken Aldape, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 20, 2008
Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology ConsortiumFaith G Davis, Beatrice S Malmer, Ken Aldape, et al.
Cancer|August 10, 2005
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumorsJ Matthew McDonald, Siew Ju See, Ivo W Tremont, et al.
Neuro-Oncology|February 13, 2010
A multigene predictor of outcome in glioblastomaHoward Colman, Li Zhang, Erik P Sulman, et al.
Science (New York, N.Y.)|July 28, 2012
Transforming fusions of FGFR and TACC genes in human glioblastomaDevendra Singh, Joseph Minhow Chan, Pietro Zoppoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium StudyTimothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.
Neuro-Oncology|March 19, 2009
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Acta Neuropathologica|May 6, 2017
Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signatureFelix Sahm, Umut H Toprak, Daniel Hübschmann, et al.
Nature Genetics|August 7, 2013
The integrated landscape of driver genomic alterations in glioblastomaVeronique Frattini, Vladimir Trifonov, Joseph Minhow Chan, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Acta Neuropathologica|December 3, 2016
Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor TaxonomyDavid N Louis, Ken Aldape, Daniel J Brat, et al.
Neuro-Oncology|December 15, 2010
Risk factors for oligodendroglial tumors: a pooled international studyBridget J McCarthy, Kristin M Rankin, Ken Aldape, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 20, 2008
Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology ConsortiumFaith G Davis, Beatrice S Malmer, Ken Aldape, et al.
Cancer|August 10, 2005
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumorsJ Matthew McDonald, Siew Ju See, Ivo W Tremont, et al.
Neuro-Oncology|February 13, 2010
A multigene predictor of outcome in glioblastomaHoward Colman, Li Zhang, Erik P Sulman, et al.
Science (New York, N.Y.)|July 28, 2012
Transforming fusions of FGFR and TACC genes in human glioblastomaDevendra Singh, Joseph Minhow Chan, Pietro Zoppoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium StudyTimothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.
Neuro-Oncology|March 19, 2009
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Acta Neuropathologica|May 6, 2017
Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signatureFelix Sahm, Umut H Toprak, Daniel Hübschmann, et al.
Nature Genetics|August 7, 2013
The integrated landscape of driver genomic alterations in glioblastomaVeronique Frattini, Vladimir Trifonov, Joseph Minhow Chan, et al.
Pageof 6